Trial Profile

Study of SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGT 501 (Primary)
Indications Polymorphic catecholergic ventricular tachycardia
Focus Adverse reactions

Most Recent Events

06 Nov 2024 According to a Solid Biosciences media release, SGT-501 IND submission for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) on track for 1H 2025
13 Mar 2024 According to a Solid Biosciences media release, company expects to file an IND for SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), in the first quarter of 2025.
08 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com